In contrast, treatment of NSCLC cells for 24 h with increasing doses of BTZ (32–128 nM) highly induced the level of HSPA1 and substantially decreased the level of HSPA2, without affecting the expression of HSPA5 and HSPA8 (Fig. 1E). The gene discussed is HSPA2; the disease is non-small cell lung carcinoma.